Novel Software Systems

What Novel Software Systems does

NOVEL Software System (Novel Software Systems) is a privately held bioinformatics and BioIT company founded in 2004 in the Novosibirsk Academgorodok district. It develops software for next-generation sequencing (NGS) interpretation, protein functional analysis, and AI-driven medical device design, serving pharmaceutical companies, diagnostic centers, scientific organizations, and biobanks across Russia, the United States, China, and the Netherlands. Its core products are Genomenal (an automated NGS annotation and clinical interpretation platform with modules for hereditary disease, oncology, pharmacogenetics, polygenic risk, and ancestry analysis), Protomenal (a neural-network service predicting protein functional properties from amino acid sequence), Autobone (an AI service that reconstructs personalized cranial implants from CT scans), and Genokarta (a Russian-language electronic encyclopedia of human genetics). The technology stack relies on in-house deep-learning models built on PyTorch, Catalyst, Scikit-learn, XGBoost, Luigi, and Docker, and integrates curated genomic knowledge bases including ClinVar, dbSNP, OMIM, GenCC, 1000Genomes, gnomAD, HPO, and Orphanet.

The company runs a hybrid revenue model combining custom software development services for biotech, pharma, and research clients with proprietary product licensing (per-seat/subscription-style distribution for Genomenal and related products) and an exclusive Russian license to PolyKnomics' P3MED polygenic risk module. Distribution is predominantly direct enterprise sales, augmented by web-based product access and the Russian Software Registry, where Genomenal is registered (No.13178) for procurement by state healthcare and research institutions. Marketing is driven by scientific publishing in international journals, academic teaching and internships at Novosibirsk State University, conference participation, and events such as the Genome IQ genetic-data hackathon and ONCOMARKERS training schools. NOVEL is founder-led by CEO Dmitry Shtokalo since inception, with a team of 50+ specialists including 15 with advanced academic degrees.

Name

Novel Software Systems

Legal name

Novel Software System

Website

https://novel-soft.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

51–100 employees

Short description

NOVEL Software System is a Russia-based bioinformatics company founded in 2004 that builds AI-powered NGS interpretation (Genomenal), protein function prediction (Protomenal), and cranial implant design (Autobone) software for pharmaceutical companies, diagnostic centers, scientific organizations, and biobanks across Russia, the USA, China, and the Netherlands.

Ownership category

akta.pro rank

Product category

Bioinformatics Software

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (5132)

SIC

Services-Prepackaged Software (7372), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)

akta.pro secondary industries

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Knowledge Management & Scientific Collaboration / Literature Intelligence (HLAGAJAN), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)

Keywords

• Bioinformatics software
• NGS data analysis
• Protein function prediction
• AI drug discovery
• Genomic data processing

Headquarters

HQ city

Novosibirsk

HQ country

Russia

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Custom Software Development Services: NOVEL develops custom software for pharma and biotech companies, scientific organizations, and diagnostic centers. The company cooperates with large international corporations and provides science-intensive solutions in data processing and complex software systems.
2. Software Products Licensing: Proprietary products including Genomenal (NGS data processing), Protomenal (protein analysis), Autobone (cranial implant modeling), and Genokarta (genetics encyclopedia) are offered as licensed software solutions.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

NOVEL develops bioinformatics and AI-driven software for genomic and proteomic analysis, including the Genomenal NGS data interpretation platform, the Protomenal neural-network-based protein function prediction service, the Autobone AI cranial implant modeling tool, and the Genokarta Russian-language genetics encyclopedia. The company also delivers custom software development services to biotech and pharmaceutical clients requiring specialized bioinformatics, machine learning, and big-data engineering capabilities.

Differentiator

Problem solved

Functional benefit

Brands

• Genomenal: Software solution for processing, annotating, and assisting in the interpretation of Next-Generation Sequencing (NGS) data of human DNA.
• Protomenal
• Autobone
• Genokarta

Products and services

• Genomenal A software solution for automated processing, annotation, and interpretation of Next-Generation Sequencing (NGS) data of human DNA, supporting hereditary disease analysis, oncology, pharmacogenetics, ancestry analysis, and polygenic risk scoring for medical geneticists and diagnostic centers.
• Protomenal A neural-network-based service that predicts the functional properties of proteins from amino acid sequence without requiring knowledge of protein structure or homologues, enabling enzyme discovery and protein engineering for biotech and pharmaceutical researchers.
• Autobone A web-based AI application that automatically models personalized cranial implants from CT scan data, building missing skull bone fragments via neural networks and assembling individualized implant designs for medical use.
• Genokarta An electronic Russian-language scientific encyclopedia of human genetics containing expert-written articles about genes, polymorphisms, and diseases, plus over 15 million auto-generated mutation annotations from dbSNP, ClinVar, SNPedia, and GWAS databases for researchers and clinicians.
• NGS Wizard A software tool for automated processing and annotation of Next-Generation Sequencing data, designed to be accessible to non-specialist users while delivering professional-grade bioinformatics capabilities for clinical and research workflows.
• Custom Bioinformatics Software Development Services Custom software development services combining molecular biology expertise with data analysis technologies for pharmaceutical companies, biotech firms, diagnostic centers, and scientific organizations requiring science-intensive bioinformatics solutions.

Quantifiable outcome

• NOVEL team won RNA expression prediction by protein expression subtask and was runner-up in all modality matching subtasks at NeurIPS 2021 Open Problems in Single Cell Analysis competition
• +1 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability13 records

Feature5 records

Partnerships

Five partnerships are on record, tiered minor and core.

• Syntol Research and Production Company LLCminorStrategic or Co-development Partner · 28 July 2025Co-organized hands-on training school on NanoFor SPS sequencing platform at ONCOMARKERS-2025 conference. Syntol is a research and production company in Russia.
• Institute of Chemical Biology and Fundamental Medicine, SB RAS (ICBFM SB RAS)minorStrategic or Co-development Partner · 28 July 2025Host organization for hands-on training school on NanoFor SPS sequencing platform at ONCOMARKERS-2025 conference. Located in Novosibirsk.
• PolyKnomics BVcoreOEM/ Whitelabel/ Licensing Partner · 17 March 2022NOVEL obtained exclusive license from Dutch software developer PolyKnomics BV for use and distribution throughout Russian Federation of P3MED software for calculating polygenic risks and predicting quantitative trait values from individual genomic data. PolyKnomics specializes in statistical and computational genomics products including GWAS-MAP and Fit2Breed platforms.
• Vector-Best JSCcoreStrategic or Co-development Partner · 7 December 2021Contract for development of AI tools for targeted protein modification. Vector-Best, the largest manufacturer of laboratory diagnostic kits in Russia (producing 600+ products for enzyme immunoassay, real-time PCR, and clinical biochemistry), partnered with NOVEL to create software for predicting effects of amino acid substitutions on target proteins to improve enzyme properties.
• Institute of Information Systems of Siberian Branch of Russian Academy of SciencesminorStrategic or Co-development Partner · 7 September 2021Joint development of software complex for automatic modeling of individual implants for skull bone defects using artificial neural networks. Project was co-financed by Ministry of Science and Innovation Policy of Novosibirsk.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• SOPHiA Genetics: Public clinical genomics interpretation platform using AI for NGS data analysis across hereditary disease, oncology, and pharmacogenomics. Directly comparable to Genomenal as a clinical NGS interpretation suite, but operates at much larger scale globally with FDA-cleared and CE-marked offerings.
• QIAGEN Digital Insights (formerly QIAGEN Bioinformatics): Major bioinformatics portfolio including Ingenuity Pathway Analysis, QIAseq pipeline, and clinical interpretation tools. Comparable to Genomenal and Protomenal as a broad life-sciences informatics offering, though QIAGEN operates at much greater scale with diversified genomics, proteomics, and molecular diagnostics reach.

Emerging players

• Arima Genomics: Genomics technology company providing 3D genome conformation analysis and bioinformatics software for NGS data interpretation. Partial overlap with NOVEL's NGS-focused workflows and serves a similar translational research and clinical research customer base.
• Lifebit Biotech: Cloud genomics platform with federated AI/ML for clinical and translational genomics. Comparable to Genomenal as a multi-omics interpretation platform, particularly in pharma R&D and population genomics use cases; smaller and earlier stage than NOVEL in some respects.
• Arcturis (formerly Genialis): AI-driven bioinformatics and multi-omics analysis platform for pharma biomarker discovery. Comparable to Protomenal and NOVEL's custom AI/ML drug discovery services, particularly around multi-omics interpretation for pharma customers.

Direct peers

• DNAnexus: Cloud-based bioinformatics platform for genomic and biomedical data analysis. Comparable as a platform serving pharma, biotech, and clinical researchers for NGS data processing and multi-omics analysis, with a similar custom-development-plus-platform business model.
• Congenica: Clinical genomics platform for rare disease and somatic cancer variant interpretation. Directly comparable to Genomenal's hereditary disease and oncology NGS interpretation workflows, serving diagnostic laboratories and clinical geneticists.
• BC Platforms: Genomics and clinical data platform for pharma R&D and personalized medicine, with strong biobank and clinical genomics offerings. Comparable to NOVEL's Genokarta and biobank analytics capabilities, also serving polygenic risk and pharmacogenetics use cases.
• Fabric Genomics: Clinical genomics interpretation platform providing AI-driven variant interpretation and clinical reporting for NGS data. Closely comparable to Genomenal's hereditary disease and oncology interpretation modules, serving similar medical geneticist and diagnostic center customers.
• Golden Helix: Bioinformatics software company providing NGS variant annotation, clinical reporting, and population genomics tools. Directly comparable to Genomenal's clinical interpretation and annotation capabilities, serving similar translational genomics and clinical diagnostics customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/novel_soft
• LinkedInlinkedin.com/company/novel-software-systems

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novel Software Systems